A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
Camrelizumab Combined Apatinib in Patients With Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors: A Single-Arm, Open-Label, Phase II Study.
Sponsor: Hunan Cancer Hospital
This PHASE2 trial investigates Hepatocellular Carcinoma and Immune Checkpoint Inhibitors and is currently ongoing. Hunan Cancer Hospital leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Jun 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
May 2021 — Sep 2023 [monthly]
Recruiting PHASE2
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hunan Cancer Hospital
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .